However, because leukemia cells treated with the inhibitor are presumed to be dependent on activation of the Jak/STAT pathway, whereas normal cells are not, ruxolitinib treatment does not appear to have consequences for non-leukemia cell survival: Jakafi® is clinically approved for treatment of myelofibrosis in adults as well as for acute graft‐versus‐host disease. Here, SOAT1 is linked to myelofibrosis.